A Basic Guide to the Propagation and Manipulation of the Clubroot Pathogen, Plasmodiophora brassicae.

Clubroot caused by the obligate parasite Plasmodiophora brassicae is a devastating disease affecting the canola industry worldwide. The socio-economic impact of clubroot can be significant, particularly in regions where Brassica crops are a major agricultural commodity. The disease can cause significant crop losses, leading to reduced yield and income for farmers.

A Hydroponic-Based Bioassay to Facilitate Phenotyping.

Clubroot, caused by the obligate parasite , is one of the most devastating diseases affecting the canola/oilseed rape () industry worldwide. Currently, the planting of clubroot-resistant (CR) cultivars is the most effective strategy used to restrict the spread and the economic losses linked to the disease. However, virulent isolates have been able to infect many of the currently available CR cultivars, and the options to manage the disease are becoming limited.

The clubroot pathogen Plasmodiophora brassicae: A profile update.

Background: Plasmodiophora brassicae is the causal agent of clubroot disease of cruciferous plants and one of the biggest threats to the rapeseed (Brassica napus) and brassica vegetable industry worldwide.

Disease Symptoms: In the advanced stages of clubroot disease wilting, stunting, yellowing, and redness are visible in the shoots. However, the typical symptoms of the disease are the presence of club-shaped galls in the roots of susceptible hosts that block the absorption of water and nutrients.

Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.

Background: There is an urgent need for biomarkers to detect pancreatic cancer in the early, potentially curable, stages.

Methods: We have used SELDI profiling to analyze serum from 75 patients with pancreatic cancer and 61 patients with nonmalignant pancreaticobiliary diseases.

Results: A peak in the SELDI spectra corresponding to a 53 residue fragment of the α-chain of fibrinogen is remarkably elevated in approximately 50% of the cancer patients.